

References

L-32

1. Walsham N, Sherwood R. Fecal calprotectin in inflammatory bowel disease. *Clin Exp Gastroenterol*. 2016; 9:21–29.
2. National Institute for Health and Care Excellence. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease. 2017.
3. Diagnosing and Managing IBD. Crohn's & Colitis Foundation of America. 2017.
4. Rogler G, Biedermann L. Clinical Utility of Biomarkers in IBD. *Current Gastroenterology Reports*. 2015;17(7):26.
5. Menees S, Powell C, Kurlander J, Goel A, Chey W. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. *Am J Gastroenterol*. 2015;110(3):444-454.
6. Holtman G, Lisman-van Leeuwen Y, Berger M, et al. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study. *Ann Fam Med*. 2016;14(5):437-445.
7. Hayes, Inc. Hayes Health Technology Brief. *Fecal calprotectin assay for monitoring disease activity in crohn's disease*. Lansdale, PA: Hayes, Inc.; 07/07/2017
8. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: management of Crohn's disease in adults. *Am J Gastroenterol*. 2018;113(4):481-517.
9. National Institute for Health and Care Excellence (NICE). Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel DG11. 2013 [Reaffirmed 2017].
10. Lasson A, Ohman L, Stotzer PO, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. *United European Gastroenterol J*. 2015;3(1):72-79.

11. Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. *Inflamm Bowel Dis*. 2017;23(6):894-902.
12. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. *Lancet*. 2018;390(10114):2779-2789.
13. Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. *J Gastrointest Liver Dis*. 2018;27(3):299-306.
14. Wright EK, Kamm MA, De Cruz, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. *Gastroenterology*. 2015;148(5):938-947.
15. World Gastroenterology Organisation (WGO). Practice Guideline - Inflammatory Bowel Disease (IBD). 2015.
16. Benitez JM, Garcia-Sanchez V. Faecal calprotectin: Management in inflammatory bowel disease. *World J Gastrointest Pathophysiol*. 2015;6(4):203-209.
17. Emile S, Gilshtein H, Wexner S. Outcome of ileal pouch anal anastomosis in patients with indeterminate colitis: A systematic review and meta-analysis. *J Crohns Colitis*. 2020.